Immunotherapies


 2020-03-24

This resource on Type 1 Diabetes Research was created in partnership with JDRF, an active partner of Beyond Type 1 at the time of publication, through the JDRF – Beyond Type 1 Alliance.


In people living with type 1 diabetes, the body’s immune system mistakes the insulin-producing beta cells as foreign objects and attacks them. Over time, people with type 1 diabetes are left with none of these beta cells, and therefore cannot produce their own insulin.

But what would happen if we could stop this immune response that attacks beta cells? This is the focus of immunotherapy research into curing type 1 diabetes. Current research is looking

  • how to prevent the immune system from attacking the islet cells in the first place
  • ways of slowing down or stopping the autoimmune response once it has begun in recently-diagnosed patients still in the honeymoon phase
  • how to stop the immune system from attacking implanted beta cells in conjunction with beta cell therapy

Ultimately, a biological cure for type 1 diabetes will likely involve a combination of beta cell therapy and immunotherapy, to both restore functioning beta cells, as well as protect them from the autoimmune response.

A Deeper Look at Immunotherapy Research with Jessica Dunne


Jessica Dunne is a Senior Director of Research at JDRF, focusing on prevention of type 1 diabetes. Recently she spoke with Beyond Type 1 about what it means to prevent T1D, the importance of populatio...MORE

Immunotherapies: The Latest News

teplizumab

FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D


The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE

The PROTECT Study 


The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE

Preventing and Delaying Type 1 Diabetes: Updates From the Teplizumab Trial


Half of those treated with teplizumab remain diabetes-free, compared to 22% of those taking placebo, and the delay in diabetes onset was close to 3 years.MORE

Immunotherapies: Trials

Go Inside the Lab with JDRF to Learn More!

Immune Therapy: Research in Boston

What makes these scientists believe they can redirect the body’s immune response to find cures for type 1 diabetes (T1D)?


To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.

WRITTEN BY BT1 Editorial Team, POSTED 03/24/20, UPDATED 01/03/23

This piece was authored collaboratively by the Beyond Type 1 Editorial Team.